Respiratory complications occur frequently in individuals living with human immunodeficiency-1 virus (HIV) infection, and there is evidence that HIV-related oxidative stress impairs alveolar macrophage immune function. We hypothesized that nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a master transcription factor that activates the antioxidant response element (ARE) and regulates antioxidant defenses, has an important role in alveolar macrophage (AMs) immune dysfunction in individuals with HIV infections. To test that hypothesis, we analyzed human monocyte-derived macrophages (MDMs) that were either infected with HIV-1 or were exposed to the HIV-related proteins gp120 and Tat ex vivo and determined that either stress affected the expression of Nrf2 and the Nrf2-ARE-dependent genes for NAD(P)H dehydrogenase, quinone 1 (NQO1) and glutamate-cysteine ligase, catalytic subunit (GCLC). We then determined that the expression of Nrf2, NQO1, and GCLC was significantly decreased in primary AMs isolated from HIV-1 transgenic rats. In parallel, treating a rat macrophage cell line (NR8383 cells) with the HIV-related proteins gp120 or Tat similarly decreased the gene and protein expression of Nrf2, NQO1, and GCLC. Further, phagocytic function was decreased in both human MDMs infected with HIV-1 and primary AMs from HIV-1 transgenic rats. Importantly, treating HIV-1-infected human MDMs or AMs from HIV-1 transgenic rats with sulforaphane (SFN, an Nrf2 activator) significantly improved their phagocytic function. The salutary effects of SFN were abrogated by silencing RNA to Nrf2 in wildtype rat macrophages. Our findings demonstrate that HIV-1 infection and exposure to HIV-1-related proteins inhibit Nrf2-ARE activity in the AMs and impair their phagocytic function. Treatments targeted at increasing Nrf2-ARE activity could, therefore, enhance lung innate immunity in people living with HIV-1.
Introduction
The advent of ART significantly increased the life span of individuals living with HIV infection, but infectious and noninfectious pulmonary complications, such as pneumonia, COPD, lung cancer, pulmonary arterial hypertension, and fibrosis are still common [1, 2] . Lung is a Mf-rich tissue, and AMs are necessary for host defense against pathogens and the regulation of immune responses. Mf function, specifically phagocytosis, is known to be impaired in HIV [3, 4] . In fact, AM functions, such as bacterial phagocytosis, are attenuated even in healthy HIV-1 + individuals who have undetectable viral loads and no history of lung infections [5] . That finding, taken together with the relatively few infected Mfs seen in patients with HIV, suggests that HIV-related viral proteins might have an important role in HIV-1-induced Mf dysfunction.
Redox homeostasis in the alveolar space is important for maintenance of cellular functions. Experimental and clinical evidence demonstrates that HIV-1-infected individuals have a significant increase in oxidative stress in the alveolar space, as reflected by lower levels of antioxidants, such as glutathione, zinc, and selenium, and higher levels of inflammatory cytokines and ROS compared with healthy subjects [6, 7] . The oxidant state in HIV-1 infection affects Mf functions and favors disease progression. Nrf2 is a transcription factor that regulates antioxidant defense systems by binding to a consensus sequence on hundreds of antioxidant genes known as the ARE. Many lung diseases are associated with impaired Nrf2 activity, including COPD and chronic alcohol ingestion [8] [9] [10] . We have recently reported impaired Nrf2 expression in alveolar epithelial cells, which consequently, impairs the epithelial barrier function in HIV-1 transgenic rats [11] . Given the known effects of HIV-1 viral protein expression on alveolar epithelial cells and the known Mf impairments seen in HIV, we hypothesized that HIV-1 viral proteins were also responsible for Mf dysfunction. Further, we speculated that the impairments were mediated by a decrease in Nrf2, given the known effects of Nrf2 on innate immune function and its impairments in other cell types exposed to HIV-related viral proteins. To evaluate Nrf2-ARE function, we focus on certain downstream effectors of Nrf2 that are known to have important roles in antioxidant defenses: GCLC, the rate-limiting step in glutathione synthesis [12] , and NQO1. These downstream effectors are both known to respond specifically to Nrf2 activation [13] .
Given our interest in the pathogenic effects of HIV-related viral proteins, we determined that certain models of HIV infections would be particularly useful to test our hypothesis. A key comparator was the direct infection of Mfs with HIV-1, for which we made use of HIV-infected, human MDMs. Next, to specifically evaluate the effects of HIV-related viral proteins, we used an HIV-1 transgenic rat model, which, although not infectious, produces viral proteins that are detectable in the alveolar space [14] . Finally, we treated a rat AM cell line (NR8383 cells) directly with 2 key HIV-related viral proteins, Tat and gp120, to assess the effects of the proteins in isolation. Importantly, these proteins have been demonstrated to have key roles in the disruption of Mf homeostasis in other organ systems [15] as well as in the lung epithelium [16] . In concert with our collaborators, we recently established a role for Tat in preventing Mf apoptosis [17] . We hypothesized, based on those findings, as well as the presence of these viral proteins in bronchoalveolar lavage fluid [14] , that Tat and gp120 may well be responsible for defects in AM function.
MATERIALS AND METHODS

Mf cell models
MDMs were isolated from the buffy coat of peripheral blood from healthy human volunteer donors by Ficoll centrifugation, according to a protocol approved by Emory University institutional review board [18] . In brief, after centrifugation, cells were cultured in serum-free RPMI-1640 at a density of 1-2 3 10 5 /well in 24-well plate coated with poly-D-lysine (SigmaAldrich, St. Louis, MO, USA) at 37°C, 5% CO 2 for 30 min, and then, nonadherent cells were removed before culture in RPMI-1640 with 10% FBS, 1% nonessential amino acid, and 1% sodium pyruvate (growth medium). After 7 d, cells were infected with or without HIV-1 viral particles at 1-2 3 10 6 50% tissue culture-infective dose/cell for 4 h and cultured with fresh growth medium for 8 d with or without treatments. HIV infection was confirmed by PCR to Tat and by Western blot to p24 (AIDS Research and Reference Reagent; National Institutes of Health, Bethesda, MD, USA). Primary rat AMs were isolated from HIV-1 Tg and WT Fischer 344 rats (Harlan Laboratories, Indianapolis, IN, USA) at 9-11 mo old and cultured in DMEM/F12 (Cellgro; Mediatech, Manassas, VA, USA) with 10% FBS (Atlanta Biologicals, Flowery Branch, GA, USA) and an antibioticantimycotic reagent (Sigma-Aldrich) at 37°C in 5% CO 2 [19] . The transgenic rat was a hemizygous NL4-3Dgag/pol, with the 39 region of gag and the 59 region of pol deleted [20] . Half of the offspring of these rats are HIV-1 transgenic and half are WT (confirmed by genotyping and dense cataracts present in the transgenic animals at birth). The breeding pattern allows for the use of littermate WT animals as controls. Food and water were provided ad libitum.
All procedures were approved by the Institutional Animal Care and Use Committee at Emory University.
NR8383 cells, a rat AM cell line (CRL-12192; ATCC, Manassas, VA), were cultured in F12K (ATCC) with 10% FBS and the same antibiotic-antimycotic reagent at 37°C in 5% CO 2 but with the FBS concentration decreased to 2% during the treatments.
Cell culture treatments. SFN was purchased from LKT Laboratories, Inc. (St. Paul, MN, USA), and all other chemicals were obtained from SigmaAldrich, except where otherwise indicated. The HIV-related viral proteins Tat and gp120 were obtained from ImmunoDX (Woburn, MA, USA) and were used at a concentration of 10 ng/ml. Heat-inactivation was performed on Tat and gp120 proteins by placement of small aliquots (containing 10 ng/ml) in a heat block at 95°C for 5 min.
RNA isolation and real-time RT-PCR. Total RNA was extracted with the Quick-RNA MicroPrep kit (Zymo Research, Irvine, CA, USA). Reverse transcription and real-time PCR (Bio-Rad Laboratories, Hercules, CA, USA) were performed as described previously using rat primer pairs [11] and the human primer pairs shown in Table 1 . PCR products for the specific genes were normalized to 9S from the same reverse-transcription sample.
Western blot. Total proteins were isolated from Mfs using 23 Laemmli sample buffer (Bio-Rad Laboratories), and protein electrophoresis and blotting were performed, as previously described [11] . After incubation with the relevant primary Ab, species-appropriate secondary Abs were applied. The immunoreactive bands were captured with ChemiDoc XRS system (Bio-Rad Laboratories) after application of an ECL substrate (GE Healthcare Life Sciences, Pittsburgh, PA, USA). The same membranes were then reprobed with an anti-GAPDH Ab for protein-loading control. For quantification, relevant bands were identified by molecular weight and quantified using the ratio of target densitometry to loading-control densitometry.
Nrf2/ARE luciferase activity assay. NR8383 cells were seeded (50,000/ well) in 96-well plates and then transfected with the Qiagen (Germantown, MD, USA) Cignal ARE reporter (a mixture of an inducible, ARE-responsive firefly luciferase construct and a constitutively expressed Renilla luciferase construct; Valencia, Santa Clarita, CA, USA) using Lipofectamine 3000 transfection reagent (Thermo Fisher Scientific, Waltham, MA, USA). For SFN experiments, SFN (5 mM) was added 18 h before lysing cells and measuring luciferase activity. A dual-luciferase reporter assay was performed as described by the manufacturer (Promega, Madison, WI, USA). Nrf2/ARE promoter activity values were expressed as ratios of arbitrary units of firefly luciferase/ Renilla luciferase activity.
Mf phagocytic function. Human MDMs or rat primary AMs were seeded at 100,000/well in 16-well tissue culture chamber slides or on coverslips with or without treatments. At the end of the treatment period, cells were incubated with fresh culture medium with or without treatment plus 1 3 10 6 pHrodo red Staphylococcus aureus BioParticles (Thermo Fisher Scientific) at 37°C, 5% CO 2 in the dark. After culture for 2 h, the Amplex Red assay. Primary rat AMs isolated from WT or HIV-1 Tg rat lungs were cultured in 24-well plates at a density of 350,000/well with DMEM/F12 plus 5% FBS for 2 d. Amplex Red (Thermo Fisher Scientific) was used to measure hydrogen peroxide (H 2 O 2 ) scavenging in the culture medium, as described in the manual by Thermo Fisher Scientific. Briefly, cells were washed with Kreb-Ringer phosphate buffer, replaced with 300 ml/well of freshly made assay-reaction mixture (100 mM of Amplex Red and 0.2 U/ml of HRP in 13 Kreb-Ringer phosphate buffer) with 5 mU/ml of glucose oxidase (Sigma-Aldrich) and cultured at 37°C for 2 h in the dark. The reaction mixture was measured for fluorescence at excitation 540 nm and emission 590 nm wavelengths [21] . The results were expressed as the percentage of H 2 O 2 scavenging in each group compared with cells from WT rats.
Nrf2 silencing RNA. Nrf2 Stealth Select RNAi (set of 3 small interfering RNA) was obtained from Thermo Fisher Scientific (Nfe2l2, oligo ID: RSS343557, RSS343558, RSS343559). All 3 small interfering RNA for Nrf2 were previously tested, and RSS343557 was chosen for this study based on its superior effectiveness. AMs from WT Fischer rats were isolated as described above and plated at a density of 200,000 cells/well and transfected with 10 nM of stealth RNAi for rat Nrf2 or negative control using the Lipofectamine transfection reagent. After 24 h, cells transfected with si-Nrf2 were treated with or without 5 mM SFN. Then, 24 h after that, cells were taken for the phagocytosis assay as described above.
Statistical analyses
A Student's t test was used for single comparisons, and 1-way ANOVA with Newman-Keuls method was used for post hoc analysis using Prism software (GraphPad, La Jolla, CA, USA). All data are presented as means 6 SEM, and significance was accepted at P , 0.05.
RESULTS
Nrf2/ARE activity is suppressed in human MDMs either infected with HIV-1 or exposed to HIV-related proteins ex vivo
We first assessed antioxidant defenses in HIV-1-infected human MDMs to better understand the extent of Mf impairment. As shown in Fig. 1A , both Nrf2 and GCLC protein expression were significantly decreased 8 d after HIV-1 viral infection (P , 0.05). To see whether HIV-1 viral protein exposure alone would have a comparable effect, MDMs were exposed to the HIV-related viral proteins gp120 and Tat in culture using concentrations similar to those previously found in the alveolar space [14] . After 3 d, both gp120 and Tat attenuated expression of Nrf2 and its downstream effectors NQO1 and GCLC proteins by 20-40% compared with unexposed MDMs (P , 0.05%; Fig. 1B ). Phagocytic index was significantly compromised as well (decrease to 61.8 6 5.3% and 66.8 6 4.4%, respectively, in gp120-or Tat-treated MDMs compared with uninfected MDMs) (Fig. 1C) . These data suggest that HIV-related viral proteins can recapitulate the effects of direct infection on Nrf2 expression and Nrf2/ARE activity. In parallel, Nrf2/ARE activity is suppressed in primary AMs isolated from HIV-1 transgenic rats and in NR8383 cells exposed to HIV-related proteins in vitro
To test the hypothesis that the inhibitory effects on Nrf2 activity were largely due to the HIV-related proteins, we made use of an HIV-1 transgenic rat model that, although not infectious, expresses a multitude of HIV-related proteins that can be found in the alveolar space of individuals living with HIV infection. As shown in Fig. 2A , Nrf2 mRNA expression was significantly decreased in primary rat AMs isolated from HIV-1 Tg rats compared with WT littermates (P , 0.05). The downstream, Nrf2-modulated antioxidants NQO1 and GCLC were also suppressed by 22% and 37% (P , 0.05), respectively (Fig. 2B) . This inhibitory effect was also found in a rat AM cell line (NR8383) treated with gp120 and Tat in vitro as shown in Fig. 2C and D. To confirm the efficacy of the HIV-related viral proteins, we treated Mfs from WT rats with heat-inactivated gp120 (higp120) and Tat (hi-Tat) and found no effects on gene expression of Nrf2 or its downstream effectors (Nrf2: 100 6 36% for untreated controls, 129 6 15% for hi-gp120, and 129 6 10% for hi-Tat; NQO1: 100 6 39% for untreated controls, 99 6 17% for hi-gp120 and 99 6 8% for hi-Tat; GCLC: 100 6 39% for untreated controls, 152 6 12% for hi-gp120 and 116 6 14% for hi-Tat; for all conditions, P . 0.05 compared with untreated controls). We previously reported a significant impairment of Mf phagocytosis and decreased levels of glutathione in the bronchoalveolar lavage fluid from HIV-1 transgenic rats [16, 19] . Given the evidence of Nrf2 impairment and our prior evidence that Nrf2 is essential for H 2 O 2 scavenging [21] , we next tested the scavenging abilities of HIV-1 transgenic rat Mfs and found them significantly reduced when compared with cells from WT littermates (Fig. 3) .
Sulforaphane treatment restores Nrf2/ARE activity and bacterial phagocytosis in human MDMs infected with HIV-1 ex vivo and in primary AMs from HIV-1 transgenic rats
Because HIV-1 infection and HIV-related viral proteins significantly impair Nrf2 activity, we hypothesized that enhancing Nrf2 with SFN, a Nrf2 activator, would increase Nrf2/ARE-dependent antioxidant responses and improve HIV-1-induced Mf dysfunction. The Nrf2/ARE dual-luciferase activity assay showed that, although Tat significantly impaired Nrf2/ARE activity, SFN significantly increased Nrf2/ARE activity by almost 8-fold in NR8383 cells (Fig. 4) . In parallel experiments, we treated HIVinfected human MDMs and HIV-1 transgenic rat Mfs with 5 mM SFN for 48 h. In both human MDMs ( Fig. 5A and B) and primary rat AMs isolated from HIV-1 Tg rats ( Fig. 6A and B) , SFN treatment resulted in significant enhancement of both mRNA and protein levels of the Nrf2/ARE-regulated antioxidants NQO1 and GCLC. In contrast, SFN treatment had no effect on Nrf2 mRNA and protein expression in either human MDMs or rat AMs, consistent with its putative actions as an activator of Nrf2 and, thereby, suggesting that preexisting Nrf2 activity was enhanced. Further, bacterial phagocytic function was restored by SFN treatment in vitro in both human MDMs (Fig. 5C ) and rat Reverse transcription and real-time PCR showed that Nrf2-and Nrf2/ARE-regulated NQO1 and GCLC mRNA expressions were significantly decreased (n = 9-18). (C and D) The rat AM cell line (NR8383 cells) was treated with the HIV-related viral protein gp120 (10 ng/ml) or Tat (10 ng/ml) for 3 d. Real-time PCR and Western blotting showed that the mRNA and protein expression of Nrf2, NQO1, and GCLC were significantly decreased (n = 3-6). Data shown are means 6 SEM. *Represents significant difference compared with WT (P , 0.05).
primary AMs (Fig. 6C) . In both cases, the number of cells showing bacterial uptake was relatively similar, independent of treatment (100% positive in control MDMs and 96% positive in HIV-infected MDMs, respectively), but SFN dramatically increased the mean fluorescence intensity (from 47.1 6 3.9% in untreated HIVinfected MDMs to 95.7 6 6.4% in SFN-treated HIV-infected MDMs). This suggests a marked improvement in the number of bacteria an individual cell could take up, rather than a restoration of function to cells that lacked it.
To further assess the effects of Nrf2 activation on phagocytic function, we tested 2 other Nrf2 activators: resveratrol and TBHQ. As shown in Fig. 6D , bacterial phagocytic function was improved, although the effect of SFN on phagocytic function was the most potent. These data suggest that activation of the Nrf2/ ARE pathway has an important role in maintaining AM innate immune function.
In parallel, we silenced Nrf2 RNA in WT rat AMs, using a protocol previously shown to achieve a knockdown of Nrf2 protein to ;35% of baseline level [13] . As predicted based on the preceding data, silencing Nrf2 significantly impaired phagocytic function as determined by the phagocytic index, with an index of 100 6 8% for cells transfected with si-Control vs. 52 6 7% for cells transfected with si-Nrf2 (P , 0.001). Treatment with SFN did not improve phagocytic index in cells transfected with si-Nrf2 (37 6 7%, P . 0.05 vs. si-Nrf2 without SFN) (Fig. 7) . A similar pattern was seen in the percentage of cells positive for phagocytosis (63 6 1% of cells transfected with si-Control vs. 28 6 4% of cells transfected with si-Nrf2, P , 0.01), and that impairment was partially (albeit significantly) reversed by SFN treatment (39 6 3% of cells, P , 0.05 vs. si-Nrf2 without SFN and P , 0.01 vs. siControl).
DISCUSSION
Even in the era of ART, lung complications (particularly pneumonia) occur frequently in individuals living with HIV. Impaired AM function is likely responsible for the increased risk of infection seen in these patients. We recently reported [16, 19] a significant decrease in glutathione level in bronchoalveolar lavage fluid, as well as attenuated phagocytosis in AMs derived from HIV-1 transgenic rats, which has been shown in the individuals with HIV/AIDS [6, [22] [23] [24] . In present study, we investigated Nrf2, a master transcription factor that has a critical role in maintenance of redox homeostasis, to understand the mechanisms of the impairment in AMs. We showed that expression of Nrf2 and its downstream effectors NQO1 and GCLC were significantly decreased in HIV-1-infected MDMs (Fig. 1A) . Importantly, Nrf2 activity was also suppressed in human MDMs directly treated with HIV-1 viral proteins, suggesting that these proteins have a significant role in AM dysfunction (Fig. 1B) . Similar findings were seen in primary AMs derived from HIV-1 transgenic rats compared with WT littermates ( Fig. 2A and B) and a rat AM cell line (NR8383 cells) treated with the HIV-1 viral proteins gp120 and Tat ( Fig. 2C and  D) . Heat-inactivation of the proteins abrogated the effect. The suppression of Nrf2/ARE activity in AMs was reversed by Nrf2 activators, including SFN in both human MDMs and primary AMs derived from HIV-1 transgenic rats, and this increase in Nrf2/ARE activity significantly improved bacterial phagocytosis (Figs. 4-6 ). The effects of SFN on phagocytosis were attenuated by silencing Nrf2 RNA (Fig. 7) . Taken together, our findings offer a mechanism for the clinical observation that AMs from patients with HIV are globally dysfunctional, despite very few actually being directly infected [5] : down-regulation of Nrf2/ARE activity by HIV-related viral proteins causes a significant imbalance of redox homeostasis, resulting in significant, but reversible, innate immune dysfunction. In that regard, the HIV-1 transgenic rat, by mimicking the alveolar space NR8383 cells were transfected with Cignal ARE reporter constructs and then cultured with Tat (10 ng/ml) for 3 d and with SFN for last 18 h. The ARE-responsive firefly luciferase activity was measured and normalized with Renilla luciferase activity for each well. The data represent the ratio of firefly luciferase to Renilla luciferase for each treatment group (means 6 SEM, n = 4-6). *Represents significant difference compared with untreated control cells (NT, P , 0.05).
# Represents significant difference compared with Tat-treated cells (P , 0.05). Rluc, Renilla luciferase.
of HIV-1-infected individuals, provides a unique tool for studying HIV-related viral protein effects on AM.
Clinical data have shown that despite an HIV-1 viral load below the limit of detection in patients with HIV/AIDS treated with ART, HIV-1 infected Mfs are found in the tissues, and proviral DNA can be detected in Mfs [5, 25] . Importantly, susceptibility to infection in individuals with HIV-1/AIDS is likely a consequence of defective AM innate immune functions, including phagocytosis, intracellular killing, and inflammatory cytokine production [24, 26] . The HIV-related viral protein Tat is known to potently inhibit phagocytosis in Mfs [27] . Although immunomodulators, such as GM-CSF or IFN for treatment of opportunistic infection have been used to enhance Mf function [4, 28, 29] , novel adjunctive therapies for HIV/AIDS, especially for those who are resistant to current ART, are sorely needed. HIV-1 infection and AIDS are known to causes a significant redox imbalance in the lungs, as we and other researchers [22, 30] have previously reported in experimental models, as well as in individuals living with HIV-1/AIDS. Macrophages are involved in scavenging the free radicals from endogenous dying cells, and the level of oxidation and local redox homeostasis is critical for modulation of the innate immune function. Nrf2, a redoxsensitive transcription factor, regulates a battery of genes to protect cells against ROS. Evidence has shown alteration in Nrf2 expression in Mfs is associated with chronic inflammation in diseases, such as COPD [9] . Nrf2 deficiency in mice leads to oxidative stress that causes DNA damage and cell death. Decreased Nrf2 in Mfs induces ROS accumulation and diminishes phagocytosis [31] . Activation of Nrf2 activity increases Mf function and stimulates the phagocytic capacity of the AM, which allows the Mfs to efficiently remove pathogens and dying cells [32] . Targeting Nrf2 signaling improves Mf bacterial clearance in individuals with COPD [9] . Nrf2 activators, such as SFN, TBHQ, dimethyl fumarate, and CDDO, have been shown to enhance Mf functions. Sussan et al. [33] reported that cigarette smoke-induced lung emphysema is clearly reduced by CDDO. Dimethyl fumarate has been shown to modulate the immune and antioxidant responses in HIV-1-infected Mfs as a novel candidate for HIV neuroprotection [34] . Although the mechanism of SFN has not been completely elucidated, it is thought to act by releasing Nrf2 from its chaperone protein (Keap1) in the cytosol, allowing it to translocate to the nucleus and bind to the ARE [35] . Our group has previously shown that SFN enhances Nrf2/ARE binding in the setting of HIV-related viral protein exposure [11] . However, SFN is also known to have a range of Nrf2-independent effects, including enhancement of the phagocytic function in peritoneal Mfs of Nrf2 2/2 mice [36] .
That said, the fact that 3 different Nrf2 activators improved bacterial phagocytosis in Mfs isolated from HIV-1 transgenic rats supports our contention that SFN is operating through enhancement of Nrf2 activity in this system. This contention is further supported by the results in Fig. 7 , which demonstrate that SFN is unable to restore the phagocytic index in cells transfected with silencing RNA to Nrf2. Whether the partial improvement in the percentage of cells positive for phagocytosis results from SFN acting through alternate pathways or through activation of preformed Nrf2 is still unclear based on this experiment, but Nrf2 does appear to have a significant role in the salutary effects of SFN on phagocytic function. We note the significant decrease in the number of cells positive for phagocytosis after transfection with si-Control relative to the percentage of positive cells under WT conditions, which is likely due to the stress caused by the transfection process. Regardless, the significant impairment in phagocytosis after transfection with si-Nrf2 still supports our overall argument. Finally, we recognize that our argument would be strengthened by the use of SFN in vivo in our HIV-1 transgenic rat, but that has, thus far, proven impractical. Given the evidence presented here, however, we think clinical investigations into the use of Nrf2 activators as adjunctive therapy in HIV-1/AIDS would be worthwhile.
In this study, a noninfectious HIV-1 transgenic rat model was used. Although there is no viral replication in the transgenic rats, the HIV-related viral proteins gp120 and Tat are detectable in serum and bronchoalveolar lavage [19, 20] . Since the introduction of ART in the late 1980s, there have been significant declines in the rates of AIDS-related deaths and hospitalizations. Many HIV-infected individuals have undetectable viral load and CD4 T cell counts within reference range. Despite that, bacterial pneumonia is still much more frequent in HIV-infected individuals. Recent evidence demonstrates that HIV-related viral proteins can directly cause pathophysiologic changes in tissues, including the blood-brain barrier and the alveolar-epithelial barrier [11, 37, 38] . Thus, HIV-1 transgenic rats can serve as an excellent model to study the effects of HIV-1 viral proteins on tissues and organs in vivo, and our group has been using it fruitfully for many years now (e.g., [16, 39, 40] ). In this study, we showed decreased Nrf2/ARE activity in HIV-1-infected or HIVrelated viral protein-treated human MDMs, and similar results in HIV-1 transgenic rats. Our data further support the hypothesis that HIV-related viral proteins have a critical role in the pathophysiology of HIV in the lung. We recognize that human peripheral monocytes are less infected by HIV-1 than localized, differentiated Mfs in the tissues [41, 42] . Further studies are necessary to investigate the change of Nrf2/ARE activity in AMs in individuals with HIV-1 infection and to study the effects of Nrf2 activators on their innate immune responses.
In summary, we found that Nrf2/ARE activity was significantly attenuated in Mfs derived from HIV-1 transgenic rats as well as 
